Health Care & Life Sciences » Pharmaceuticals | MaYinglong Pharmaceutical Group Co. Ltd.

MaYinglong Pharmaceutical Group Co. Ltd. | Income Statement

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,586
1,605
1,770
2,086
1,729
2,176
Cost of Goods Sold (COGS) incl. D&A
917
957
1,097
1,347
885
1,220
Gross Income
670
648
674
740
844
956
SG&A Expense
486
463
465
498
582
650
EBIT
183
186
205
235
262
306
Unusual Expense
2
1
2
1
48
157
Non Operating Income/Expense
15
14
25
30
40
10
Interest Expense
5
6
8
6
3
5
Pretax Income
216
222
243
272
353
182
Income Tax
37
30
37
47
56
27
Equity in Affiliates
1
-
4
7
12
9
Consolidated Net Income
178
192
211
233
309
165
Net Income
186
201
223
250
320
176
Net Income After Extraordinaries
186
201
223
250
320
176
Net Income Available to Common
186
201
223
250
320
176
EPS (Basic)
0.43
0.47
0.52
0.58
0.74
0.41
Basic Shares Outstanding
431
431
431
431
431
431
EPS (Diluted)
0.43
0.47
0.52
0.58
0.74
0.41
Diluted Shares Outstanding
431
431
431
431
431
431
EBITDA
216
225
238
276
307
352
Other Operating Expense
1
-
4
6
-
-
Non-Operating Interest Income
16
18
11
7
6
23
Minority Interest Expense
9
9
12
17
11
12

About MaYinglong Pharmaceutical Group Co.

View Profile
Address
No. 100 Zhoujiawan
Wuhan Hubei 430064
China
Employees -
Website -
Updated 07/08/2019
Mayinglong Pharmaceutical Group Co., Ltd. engages in the manufacture of pharmaceutical products. It involves in the following business activities through its subsidiaries: operation of anorectal hospitals and clinics; and retail and wholesale of medicines. Its products include hemorrhoids cream, treatment for skin disease, and cough suppressants.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.